Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
Afatinib, as the first-line treatment for non-small cell lung cancer (NSCLC), causes severe gastrointestinal adverse reactions that greatly affect patients' quality of life and even potentially result in treatment discontinuation. Multiple dose adjustments and concomitant use of anti-diarrheal medic...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2023-09-01
|
| Col·lecció: | Neoplasia: An International Journal for Oncology Research |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1476558623000477 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|